Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer
β Scribed by Patrick Ross Jr.; John Grecula; Tanios Bekaii-Saab; Miguel Villalona-Calero; Gregory Otterson; Cynthia Magro
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 273 KB
- Volume
- 38
- Category
- Article
- ISSN
- 0196-8092
No coin nor oath required. For personal study only.
β¦ Synopsis
Background and objectives:
Incorporation of photodynamic therapy (pdt) into the induction therapy regimen utilized for treatment of locally advanced primary non-small cell bronchogenic carcinoma (nsclc) is explored.
Study design/materials and methods:
We present a retrospective review of 41 patients diagnosed with non-metastatic nsclc who underwent induction pdt with chemotherapy and/or radiation.
Results:
Fifty percent of patients initially deemed unresectable, were able to undergo definitive surgical resection after trimodality induction therapy. twenty-seven percent of patients considered to require pneumonectomy were able to have a lobectomy. the pathological stage was less than the preinduction clinical stage in 14 of 22 cases; of which four patients had no residual tumor. there was no 30/90-day postoperative mortality. mean survival was 35.9 months (lobectomy), 25.5 months (pneumonectomy) and 14.7 months (no surgery). median survival was 78% (12 months) and 46% (36 months). the main postoperative complication following pneumonectomy was bronchopleural fistula formation. all patients who developed this complication had undergone trimodality induction therapy. incorporation of pdt into the induction arsenal for patients with loco-regionally advanced nsclc may be safely performed.
Conclusions:
Pdt may define an alternative induction strategy for patients requiring pneumonectomy; further studies exploring the true efficacy of pdt as an induction modality are encouraged.
π SIMILAR VOLUMES
## Abstract ## Purpose The role of photodynamic therapy (PDT) in the treatment of small cancers has been established in several clinical studies. Here, we report on the efficacy of PDT for early inoperable or recurrent nonβsmallβcell lung cancer (NSCLC). ## Methods and Materials From June 1989 t
Docetaxel (DOC), a member of the taxane family of anticancer drugs, binds to tubulin and produces unnaturally stable microtubules that induce cell death. DOC is used clinically alone or in combination with other compounds to treat advanced stages of cancer. We have treated the human lung cancer cell
It has been reported that genes regulating apoptosis may play a role in tumoral angiogenesis. This study examined the relationship between tumour vascularization, a measure of tumour angiogenesis, and bcl-2 and p53 expression in operable non-small-cell lung cancer (NSCLC). The relationship between b
## Abstract Activation of the epidermal growth factor receptor (EGFR) contributes to the pathogenesis of nonβsmallβcell lung carcinomas (NSCLC) and gefitinib, a selective reversible EGFR inhibitor, is effective in treating patients with NSCLC. However, clinical resistance to gefitinib is a frequent